Nintedanib** is indicated in combination with docetaxel for the treatment of adult patients with locally
advanced, metastatic or locally recurrent
Nintedanib is a triple angiokinase inhibitor blocking the kinase activity of vascular
endothelial growth factor
Nintedanib, when added to docetaxel, demonstrated over one year (12.6 months) median overall survival for patients
with advanced lung cancer with adenocarcinoma after
The approval of nintedanib in the EU is primarily based on the positive results of the LUME-Lung 1 study of with over 1300 patients from 27 countries.2For further information on nintedanib please see:
- VARGATEF Summary of Product Characteristics available at: http://ec.europa.eu/health/documents/community-register/2014/20141121130020/anx_130020_en.pdf Accessed: March 2016.
- Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients
with previously treated
non-smallcell lung cancer (LUME-Lung 1):a phase 3, double-blind,randomised controlled trial. Lancet Oncol 2014;15:143-155.